Synthesis, evaluation and structure-activity relationships of triazine dimers as novel antiviral agents.

[1]  Robert A. Domaoal,et al.  Discovery of dimeric inhibitors by extension into the entrance channel of HIV-1 reverse transcriptase. , 2012, Bioorganic & medicinal chemistry letters.

[2]  Christophe M. L. Vande Velde,et al.  Novel diarylpyridinones, diarylpyridazinones and diarylphthalazinones as potential HIV-1 nonnucleoside reverse transcriptase inhibitors (NNRTIs). , 2011, Bioorganic & medicinal chemistry.

[3]  S. Pelly,et al.  Imidazo[1,2-a]pyridin-3-amines as potential HIV-1 non-nucleoside reverse transcriptase inhibitors. , 2011, Bioorganic & medicinal chemistry.

[4]  E. De Clercq,et al.  A time-of–drug addition approach to target identification of antiviral compounds , 2011, Nature Protocols.

[5]  B. Clotet,et al.  Diarylpyrimidine-dihydrobenzyloxopyrimidine hybrids: new, wide-spectrum anti-HIV-1 agents active at (sub)-nanomolar level. , 2011, Journal of medicinal chemistry.

[6]  Catherine Caillet,et al.  Synthesis and biological evaluation of aryl-phospho-indole as novel HIV-1 non-nucleoside reverse transcriptase inhibitors. , 2011, Journal of medicinal chemistry.

[7]  Hong Lu,et al.  Design, synthesis, and evaluation of diarylpyridines and diarylanilines as potent non-nucleoside HIV-1 reverse transcriptase inhibitors. , 2010, Journal of medicinal chemistry.

[8]  E. De Clercq,et al.  Hybrid diarylbenzopyrimidine non-nucleoside reverse transcriptase inhibitors as promising new leads for improved anti-HIV-1 chemotherapy. , 2010, Bioorganic & medicinal chemistry.

[9]  Xianfeng Lin,et al.  Discovery of piperidin-4-yl-aminopyrimidines as HIV-1 reverse transcriptase inhibitors. N-benzyl derivatives with broad potency against resistant mutant viruses. , 2010, Bioorganic & medicinal chemistry letters.

[10]  Hong Lu,et al.  Diarylaniline derivatives as a distinct class of HIV-1 non-nucleoside reverse transcriptase inhibitors. , 2010, Journal of medicinal chemistry.

[11]  C. Pannecouque,et al.  Synthesis and anti-HIV activity of 2-naphthyl substituted DAPY analogues as non-nucleoside reverse transcriptase inhibitors. , 2010, Bioorganic & medicinal chemistry.

[12]  William L. Jorgensen,et al.  Eastern extension of azoles as non-nucleoside inhibitors of HIV-1 reverse transcriptase; cyano group alternatives. , 2010, Bioorganic & medicinal chemistry letters.

[13]  E. De Clercq,et al.  Synthesis and biological evaluation of 4-(hydroxyimino)arylmethyl diarylpyrimidine analogues as potential non-nucleoside reverse transcriptase inhibitors against HIV. , 2010, Bioorganic & Medicinal Chemistry.

[14]  Hong Lu,et al.  Discovery of diarylpyridine derivatives as novel non-nucleoside HIV-1 reverse transcriptase inhibitors. , 2009, Bioorganic & medicinal chemistry letters.

[15]  C. Herrera,et al.  Reverse Transcriptase Inhibitors as Potential Colorectal Microbicides , 2009, Antimicrobial Agents and Chemotherapy.

[16]  D. Stammers,et al.  Structural basis for drug resistance mechanisms for non-nucleoside inhibitors of HIV reverse transcriptase. , 2008, Virus research.

[17]  C. Sahlberg,et al.  Development of Non-Nucleoside Reverse Transcriptase Inhibitors for Anti- HIV Therapy , 2008 .

[18]  K. Hertogs,et al.  Synthesis of novel diarylpyrimidine analogues of TMC278 and their antiviral activity against HIV-1 wild-type and mutant strains. , 2007, European journal of medicinal chemistry.

[19]  K. Hertogs,et al.  Synthesis of novel diarylpyrimidine analogues and their antiviral activity against human immunodeficiency virus type 1. , 2005, Journal of medicinal chemistry.

[20]  Stephen H Hughes,et al.  In search of a novel anti-HIV drug: multidisciplinary coordination in the discovery of 4-[[4-[[4-[(1E)-2-cyanoethenyl]-2,6-dimethylphenyl]amino]-2- pyrimidinyl]amino]benzonitrile (R278474, rilpivirine). , 2005, Journal of medicinal chemistry.

[21]  Bart De Corte,et al.  From 4,5,6,7-tetrahydro-5-methylimidazo[4,5,1-jk](1,4)benzodiazepin-2(1H)-one (TIBO) to etravirine (TMC125): fifteen years of research on non-nucleoside inhibitors of HIV-1 reverse transcriptase. , 2005 .

[22]  Koen Andries,et al.  TMC125, a Novel Next-Generation Nonnucleoside Reverse Transcriptase Inhibitor Active against Nonnucleoside Reverse Transcriptase Inhibitor-Resistant Human Immunodeficiency Virus Type 1 , 2004, Antimicrobial Agents and Chemotherapy.

[23]  Rudi Pauwels,et al.  New non-nucleoside reverse transcriptase inhibitors (NNRTIs) in development for the treatment of HIV infections. , 2004, Current opinion in pharmacology.

[24]  H. M. Vinkers,et al.  Roles of conformational and positional adaptability in structure-based design of TMC125-R165335 (etravirine) and related non-nucleoside reverse transcriptase inhibitors that are highly potent and effective against wild-type and drug-resistant HIV-1 variants. , 2004, Journal of medicinal chemistry.

[25]  R. Pauwels,et al.  Evolution of anti-HIV drug candidates. Part 3: Diarylpyrimidine (DAPY) analogues. , 2001, Bioorganic & medicinal chemistry letters.

[26]  R. Pauwels,et al.  Evolution of anti-HIV drug candidates. Part 2: Diaryltriazine (DATA) analogues. , 2001, Bioorganic & medicinal chemistry letters.

[27]  P. Anderson,et al.  L-743, 726 (DMP-266): a novel, highly potent nonnucleoside inhibitor of the human immunodeficiency virus type 1 reverse transcriptase , 1995, Antimicrobial agents and chemotherapy.

[28]  Jianping Ding,et al.  Locations of anti-AIDS drug binding sites and resistance mutations in the three-dimensional structure of HIV-1 reverse transcriptase. Implications for mechanisms of drug inhibition and resistance. , 1994, Journal of molecular biology.

[29]  L. Resnick,et al.  U-90152, a potent inhibitor of human immunodeficiency virus type 1 replication , 1993, Antimicrobial Agents and Chemotherapy.

[30]  J. Adams,et al.  Inhibition of HIV-1 replication by a nonnucleoside reverse transcriptase inhibitor. , 1990, Science.

[31]  E. De Clercq,et al.  Recent advances in DAPYs and related analogues as HIV-1 NNRTIs. , 2011, Current medicinal chemistry.